1
|
De Rycke O, Védie AL, Guarneri G, Nin F, De Flori C, Hentic O, Idri S, Sauvanet A, Rebours V, Cros J, Couvelard A, Ruszniewski P, de Mestier L. O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors. Pancreatology 2020; 20:1718-1722. [PMID: 33032924 DOI: 10.1016/j.pan.2020.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2020] [Revised: 09/11/2020] [Accepted: 09/19/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of patients with blood type O is better for pancreatic adenocarcinoma, although this has not been extensively explored in pancreatic neuroendocrine tumors (PanNET). OBJECTIVE To assess the influence of the ABO and Rhesus blood types on the risk of recurrence in patients who underwent curative intent PanNET surgical resection. METHODS All consecutive patients operated on for well-differentiated panNET in an expert center from 2003 to 2018 were retrospectively included. Blood group, Rhesus system, demographic and clinical data were collected. The primary endpoint was recurrence free survival (RFS). Factors associated with RFS were explored using Cox proportional hazard models. RESULTS Overall, 300 patients (male 43%) were included, median age 54 years old (IQR 45-64). The ABO blood group distribution was similar to that of the French population. There was no association between blood group and tumor features. The median postoperative follow-up was 43.9 months (17.0-77.8). The 5- and 10-year RFS rates were 85 ± 4% and 71 ± 13% in O RhD + patients, versus 72 ± 4% and 63 ± 6% otherwise, respectively (p = 0.035). The O RhD + blood group was associated with a decreased risk of recurrence (HR 0.34, 95% CI [0.15-0.75]), p = 0.007 in multivariable analysis adjusted for age, ki67, functioning syndrome, resection margins, tumor size, lymph node status, oncogenetic syndrome. CONCLUSIONS After curative-intent surgical resection for PanNET, patients with a non-O RhD + blood group may have an increased risk of recurrence and could benefit from closer follow-up.
Collapse
Affiliation(s)
- Ophélie De Rycke
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France; Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
| | - Anne-Laure Védie
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France; Université de Paris, France
| | - Giovanni Guarneri
- Department of Hepato-Bilio-Pancreatic Surgery, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France
| | - Frédéric Nin
- Établissement Français du Sang Ile de France, Beaujon University Hospital (APHP), Clichy, France
| | - Céline De Flori
- INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
| | - Olivia Hentic
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France
| | - Salim Idri
- Établissement Français du Sang Ile de France, Beaujon University Hospital (APHP), Clichy, France
| | - Alain Sauvanet
- Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; Department of Hepato-Bilio-Pancreatic Surgery, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France
| | - Vinciane Rebours
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France; Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
| | - Jérôme Cros
- Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; Department of Pathology, ENETS Centre of Excellence, Bichat/Beaujon University Hospital (APHP), Paris/Clichy, France
| | - Anne Couvelard
- Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France; Department of Pathology, ENETS Centre of Excellence, Bichat/Beaujon University Hospital (APHP), Paris/Clichy, France
| | - Philippe Ruszniewski
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France; Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France
| | - Louis de Mestier
- Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon University Hospital (APHP), Clichy, France; Université de Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation, Paris, France.
| |
Collapse
|
2
|
Stakišaitis D, Juknevičienė M, Ulys A, Žaliūnienė D, Stanislovaitienė D, Šepetienė R, Slavinska A, Sužiedėlis K, Lesauskaitė V. ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity. Oncol Lett 2018; 16:1321-1331. [PMID: 30061952 PMCID: PMC6063046 DOI: 10.3892/ol.2018.8749] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Accepted: 04/16/2018] [Indexed: 02/07/2023] Open
Abstract
The aim of the present study was to assess the ABO blood group polymorphism association with prostate, bladder and kidney cancer, and longevity. The following data groups were analyzed: Prostate cancer (n=2,200), bladder cancer (n=1,530), renal cell cancer (n=2,650), oldest-old (n=166) and blood donors (n=994) groups. The data on the ABO blood type frequency and odds ratio in prostate cancer patients revealed a significantly higher blood group B frequency (P<0.05); the pooled men and women, separate men bladder cancer risk was significantly associated with the blood group B (P<0.04); however, no such association was identified in the female patients. The blood group O was observed to have a significantly decreased risk of bladder cancer for females (P<0.05). No significance for the ABO blood group type in the studied kidney cancer patients was identified. A comparison of the oldest-old and blood donor groups revealed that blood group A was significantly more frequent and blood type B was significantly rarer in the oldest-olds (P<0.05). The results of the present study indicated that blood type B was associated with the risk of prostate and bladder cancer, and could be evaluated as a determinant in the negative assocation with longevity. Blood types O and A may be positive factors for increasing the oldest-old age likelihood. The clustering analysis by the ABO type frequency demonstrated that the oldest-olds comprised a separate cluster of the studied groups.
Collapse
Affiliation(s)
- Donatas Stakišaitis
- Laboratory of Molecular Oncology, National Cancer Institute, LT-08660 Vilnius, Lithuania
| | - Milda Juknevičienė
- Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
| | - Albertas Ulys
- Oncosurgery Clinics, National Cancer Institute, LT-08660 Vilnius, Lithuania
| | - Dalia Žaliūnienė
- Department of Ophtalmology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
| | - Daiva Stanislovaitienė
- Department of Ophtalmology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
| | - Ramunė Šepetienė
- Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
| | | | - Kęstutis Sužiedėlis
- Laboratory of Molecular Oncology, National Cancer Institute, LT-08660 Vilnius, Lithuania
| | - Vita Lesauskaitė
- Department of Geriatrics, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
| |
Collapse
|